{"disease":{"id":"gilles-de-la-tourette-s-syndrome","name":"Gilles de la Tourette's syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"haloperidol","indication_name":"Gilles de la Tourette's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"haloperidol","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Typical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pimozide","indication_name":"Gilles de la Tourette's syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orap","generic_name":"PIMOZIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 7","drug_class":"Typical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05233306","title":"Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Max Planck Institute for Human Cognitive and Brain Sciences","has_results":false},{"nct_id":"NCT05232955","title":"Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Max Planck Institute for Human Cognitive and Brain Sciences","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}